Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) Other Operating Expenses: 2020-2025

Historic Other Operating Expenses for Xeris Biopharma Holdings (XERS) over the last 5 years, with Sep 2025 value amounting to $13.7 million.

  • Xeris Biopharma Holdings' Other Operating Expenses fell 15.93% to $13.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.9 million, marking a year-over-year increase of 13.49%. This contributed to the annual value of $47.7 million for FY2024, which is 20.73% up from last year.
  • Xeris Biopharma Holdings' Other Operating Expenses amounted to $13.7 million in Q3 2025, which was down 6.17% from $14.6 million recorded in Q2 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' Other Operating Expenses peaked at $16.3 million during Q3 2024, and registered a low of $1.8 million during Q1 2021.
  • In the last 3 years, Xeris Biopharma Holdings' Other Operating Expenses had a median value of $10.9 million in 2023 and averaged $11.5 million.
  • As far as peak fluctuations go, Xeris Biopharma Holdings' Other Operating Expenses slumped by 41.69% in 2021, and later skyrocketed by 392.00% in 2022.
  • Quarterly analysis of 5 years shows Xeris Biopharma Holdings' Other Operating Expenses stood at $5.4 million in 2021, then surged by 65.51% to $9.0 million in 2022, then grew by 14.21% to $10.3 million in 2023, then grew by 18.56% to $12.2 million in 2024, then fell by 15.93% to $13.7 million in 2025.
  • Its Other Operating Expenses was $13.7 million in Q3 2025, compared to $14.6 million in Q2 2025 and $11.4 million in Q1 2025.